Compare HROW & NBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HROW | NBR |
|---|---|---|
| Founded | 1998 | 1952 |
| Country | United States | Bermuda |
| Employees | 373 | 13900 |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | N/A | N/A |
| Metric | HROW | NBR |
|---|---|---|
| Price | $31.15 | $106.73 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 7 |
| Target Price | $69.86 | ★ $75.00 |
| AVG Volume (30 Days) | ★ 842.7K | 295.0K |
| Earning Date | 05-11-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $31.62 | $3.65 |
| Revenue Next Year | $50.77 | $4.88 |
| P/E Ratio | ★ N/A | $4.33 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.21 | $23.27 |
| 52 Week High | $54.98 | $112.90 |
| Indicator | HROW | NBR |
|---|---|---|
| Relative Strength Index (RSI) | 32.55 | 64.54 |
| Support Level | $29.15 | $75.43 |
| Resistance Level | $41.67 | N/A |
| Average True Range (ATR) | 1.87 | 4.34 |
| MACD | -0.85 | 0.34 |
| Stochastic Oscillator | 18.64 | 68.31 |
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
Nabors Industries Ltd owns and operates land-based drilling rig fleets and is a provider of offshore platform rigs in the United States and international markets. It also provides performance tools, directional drilling services, tubular running services, and technologies. The company has four reportable segments: U.S. Drilling, International Drilling, Drilling Solutions, and Rig Technologies. The key revenue of the company is generated from International Drilling.